Product Theater: Aczone Proven Effective for Acne Lesion Reduction
Dr. Julie Harper lectures on Aczone (dapsone) Gel 5% for the treatment of acne at this year’s SDPA Fall Conference in San Diego, CA.
Acne is among the most common complaints in dermatology offices across the country. Many patients come longing for a cure, however what can be realistically offered is education, empathy, and a treatment plan to lessen visible irritation. In her lecture at the SDPA Fall Conference in San Diego, Dr. Julie Harper spoke for Allergan about the efficacy of Aczone (dapsone) for treating acne.
Dr. Harper first provided an overview of the pathophysiology of acne. The classic view of acne, says Harper, is unilateral: normal-appearing skin to microcomedone, to noninflammatory lesions, to inflammatory lesions, to resolution (which may include scarring and dyschromia). With more research, however, a cyclical understanding of acne is coming to the forefront. In this evolving view, inflammation is present throughout the various stages. Dr. Harper mentioned a case from 2003 in which biopsies were taken from the lesion site as well as the visually-uninvolved skin. Analysis showed that inflammation was present regardless of the skin appearance and likely present before the microcomedone formation.
When polling acne patients on their highest concerns, many listed the inflammatory acne lesions as their number one concern, and close behind this was the comedonal acne lesions. Medical providers can now step in to provide the topical gel Aczone that has been proven to reduce these lesion counts that concern their patients. Aczone Gel 5%, the only acne treatment with topical dapsone, has had clinical success in reducing lesion counts from baseline to week 12. In one long-term study, 41% of Aczone patients achieved clinical success verses the 33% of the vehicle patients. Less that 1% of patients experienced severe erythema, dryness, or oiliness and no patients discontinued use due to adverse events.
Dr. Harper mentioned that alongside a treatment plan, patient education and support are necessary components to time with our patients. Emphasize that acne is a chronic disease that requires long-term management, and take a few extra minutes to explain medications to your patients. By being aware of the impact that acne may have of the social and emotional aspects of the patient’s life, medical providers can provide holistic, patient-centered care.